Articles related to CHECKPOINT INHIBITORS

In June 2020, the US Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik, Epizyme), an oral EZH2 inhibitor for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL). Clinical Advances in Hematology & Oncology takes a closer look at this new treatment through a conversation with Dr. Connie Lee Batlevi from MSKCC.

Olaparib, a PARP inhibitor, is approved for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) in germline (g)BRCA1/2 mutation carriers. Find out whether the results from this latest report will emphasize the value of molecular characterization (homologous recombination (HR)–related genes other than BRCA1/2) for treatment decisions in MBC.

The findings, recently published in the Journal of Thoracic Oncology, suggested that patients with ALK rearrangements may benefit from prophylactic anticoagulation, and venous thromboembolism risk prediction scores may improve if ALK rearrangement status is incorporated.

In this Original Investigation, JAMA Oncology explores the CheckMate 143 Phase 3 trial, asking whether PD-1 immune checkpoint inhibition with nivolumab improves overall survival compared with bevacizumab treatment for patients with recurrent glioblastoma.

Already approved to treat ovarian cancer, Rubraca (rucaparib) has been granted accelerated approval as the first PARP inhibitor to treat certain patients with prostate cancer, offering a completely new approach for physicians.